(PRs) among 38 response-evaluable non-small cell lung cancer (NSCLC) patients (ORR 26%), including three of seven squamous cell NSCLC patients (ORR 43%)Five confirmed PRs among 19 response-evaluable ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology ...
Please replace the release with the following corrected version due to multiple revisions.The updated release reads:MOUNTAIN VALLEY MD ANNOUNCES APPOINTMENT OF ADVISORS AND STOCK OPTION GRANTSMountain ...
Posters highlight antigen-independent delivery, differentiated efficacy and broad payload versatility of ultra pH-sensitive ...
Data demonstrate a scalable approach to better understand tumor cell behavior and inform drug developmentDALLAS--(BUSINESS WIRE)--SingleCell Biotechnology, a biotechnology company developing ...
Encouraging early results catalyze continued investigation in the MATISSE Phase 2 study evaluating IPH5201, a first-in-class ...
Data highlight biomarker-linked activity and in vivo efficacy of STX-6398, supporting small-molecule CKAP2 modulation as a ...
Ultrasensitive, structural variant-based ctDNA monitoring reliably tracks therapeutic response and predicts progression in metastatic breast cancer, and is a strong independent prognostic marker in ...
The Electronic Skin Market is emerging as one of the most transformative segments within advanced materials and wearable ...
Clinically studied curcumin formulation demonstrating significantly enhanced absorption versus standard 95% curcuminoid extracts.Derived predominantly from turmeric (~98.5%), maintaining a composition ...
The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of checkpoint inhibitor refractory unresectable or metastatic melanoma with PD-L1+ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results